BRPI0610132B8 - composição farmacêutica, kit e utilização de uma composição - Google Patents

composição farmacêutica, kit e utilização de uma composição

Info

Publication number
BRPI0610132B8
BRPI0610132B8 BRPI0610132A BRPI0610132A BRPI0610132B8 BR PI0610132 B8 BRPI0610132 B8 BR PI0610132B8 BR PI0610132 A BRPI0610132 A BR PI0610132A BR PI0610132 A BRPI0610132 A BR PI0610132A BR PI0610132 B8 BRPI0610132 B8 BR PI0610132B8
Authority
BR
Brazil
Prior art keywords
composition
pharmaceutical composition
kit
pharmaceutical
ionone
Prior art date
Application number
BRPI0610132A
Other languages
English (en)
Inventor
Remmal Adnane
Original Assignee
Advanced Scient Developments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scient Developments filed Critical Advanced Scient Developments
Publication of BRPI0610132A2 publication Critical patent/BRPI0610132A2/pt
Publication of BRPI0610132B1 publication Critical patent/BRPI0610132B1/pt
Publication of BRPI0610132B8 publication Critical patent/BRPI0610132B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição farmacêutica, kit e utilização de uma composição. a invenção refere-se a uma composição farmacêutica. a composição farmacêutica da invenção compreende pelo menos uma primeira substância terapeuticamente ativa escolhida dentre o carveol, o timol, o eugenol, o borneol, o carvacrol, a alfa-ionona, a beta-ionona e os isômeros e derivados e misturas destes, e pelo menos uma segunda substância terapeuticamente ativa que é um antifúngico. a invenção encontra aplicação no domínio farmacêutico.
BRPI0610132A 2005-05-13 2006-05-15 composição farmacêutica, kit e utilização de uma composição BRPI0610132B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2005/001317 WO2006120496A1 (fr) 2005-05-13 2005-05-13 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l’ eugenol, le thymol, le borneol, et le carvacrol
IBPCT/IB2005/001317 2005-05-13
PCT/IB2006/001329 WO2006120565A2 (fr) 2005-05-13 2006-05-15 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol, et les i0n0nes alpha- et beta-.

Publications (3)

Publication Number Publication Date
BRPI0610132A2 BRPI0610132A2 (pt) 2012-09-25
BRPI0610132B1 BRPI0610132B1 (pt) 2020-08-11
BRPI0610132B8 true BRPI0610132B8 (pt) 2021-05-25

Family

ID=35427301

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610132A BRPI0610132B8 (pt) 2005-05-13 2006-05-15 composição farmacêutica, kit e utilização de uma composição

Country Status (13)

Country Link
US (1) US20080214568A1 (pt)
EP (1) EP1879654B1 (pt)
JP (1) JP5410747B2 (pt)
CN (1) CN101189044B (pt)
BR (1) BRPI0610132B8 (pt)
CA (1) CA2607561C (pt)
DK (1) DK1879654T3 (pt)
EA (1) EA014068B1 (pt)
ES (1) ES2390472T3 (pt)
MA (1) MA29907B1 (pt)
PT (1) PT1879654E (pt)
TN (1) TNSN07425A1 (pt)
WO (2) WO2006120496A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041585T2 (hu) 2004-09-28 2019-05-28 Avivagen Inc Kompozíciók és eljárások súlygyarapodás és táplálék konverzió elõsegítésére
PL2214656T3 (pl) * 2007-10-26 2019-06-28 Avivagen Inc. Kompozycje i sposoby wzmacniania odpowiedzi immunologicznej
CA2771204C (en) 2009-04-30 2017-09-19 Chemaphor Inc. Methods and compositions for improving the health of animals
WO2011036048A1 (en) 2009-09-24 2011-03-31 Unilever Nv Disinfecting agent comprising eugenol, terpineol and thymol
BR112013013085B1 (pt) 2010-12-07 2018-02-14 Unilever N.V. Composição de cuidados orais, enxaguante bucal, creme dental, dentífrico, método para desinfetar a cavidade oral e uso de uma composição
CN102550610B (zh) * 2010-12-07 2014-12-10 菲勒斯株式会社 含有从红松球果中提取的植物杀菌素的天然抗菌剂及包含它的水果病害防除原料
JP2014509845A (ja) * 2011-02-07 2014-04-24 フイルメニツヒ ソシエテ アノニム 抗真菌性のフレーバリング成分およびフレーバリング組成物
EA024551B1 (ru) 2011-11-03 2016-09-30 Юнилевер Н.В. Индивидуальная композиция для очищения
JP5925605B2 (ja) * 2012-06-04 2016-05-25 花王株式会社 リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
WO2016057563A1 (en) 2014-10-08 2016-04-14 Pacific Northwest Diabetes Research Institute Methods and compositions for increasing the potency of antifungal agents
CN104642326B (zh) * 2015-02-16 2016-02-10 河南科技学院 一种含戊苯吡菌胺和香芹酚的杀菌组合物及其用途
WO2017209588A2 (fr) 2016-06-02 2017-12-07 Advanced Scientific Developements Formulation pharmaceutique de cinéol et d'amoxicilline
EP3490552B1 (en) 2016-07-26 2022-11-23 University of Southern California Selective bromodomain inhibition of fungal bdf1
CN113116916B (zh) * 2021-05-25 2023-07-04 河北医科大学第二医院 一种治疗妇科疾病的药物组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294645A (en) * 1993-06-14 1994-03-15 Doyle E. Chastain Using menth-1-en-9-ol to kill bacteria, yeast, and fungi
CA2106032C (en) * 1993-09-13 1995-11-07 Gamini Weeratunga Methods for the manufacture of fluconazole and forms thereof, intermediates useful in the manufacture thereof, and combinations comprising fluconazole
WO1995019179A1 (en) * 1994-01-14 1995-07-20 Xoma Corporation Anti-fungal methods and materials
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6319507B1 (en) * 1997-05-02 2001-11-20 Kobo Products, Inc. Agar gel bead composition and method
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
AU2002217316A1 (en) * 2001-01-03 2002-07-30 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
JP2002284702A (ja) * 2001-01-19 2002-10-03 Teika Seiyaku Kk 外用抗真菌製剤
WO2002062316A1 (de) * 2001-02-08 2002-08-15 Vectron Therapeutics Ag Invasomen zur therapie von erkrankungen, ihre herstellung und verwendung
JP2002363070A (ja) * 2001-06-06 2002-12-18 Yuutoku Yakuhin Kogyo Kk 経皮吸収貼付剤
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
AU2002360517A1 (en) * 2001-12-07 2003-06-23 Ximed Group Plc Respiratory infection prevention and treatment with terpene-containing compositions
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
US20050014730A1 (en) * 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil

Also Published As

Publication number Publication date
DK1879654T3 (da) 2012-08-20
PT1879654E (pt) 2012-08-29
JP5410747B2 (ja) 2014-02-05
WO2006120565A3 (fr) 2007-08-23
EA200702482A1 (ru) 2008-04-28
JP2008540506A (ja) 2008-11-20
TNSN07425A1 (fr) 2009-03-17
ES2390472T3 (es) 2012-11-13
EP1879654B1 (fr) 2012-07-04
CA2607561A1 (fr) 2006-11-16
US20080214568A1 (en) 2008-09-04
BRPI0610132A2 (pt) 2012-09-25
CN101189044A (zh) 2008-05-28
CN101189044B (zh) 2011-12-07
WO2006120565A2 (fr) 2006-11-16
EP1879654A2 (fr) 2008-01-23
EA014068B1 (ru) 2010-08-30
WO2006120496A1 (fr) 2006-11-16
CA2607561C (fr) 2014-02-04
BRPI0610132B1 (pt) 2020-08-11
MA29907B1 (fr) 2008-11-03

Similar Documents

Publication Publication Date Title
BRPI0610125B8 (pt) composição farmacêutica, kit e utilização de uma composição
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
PE20091394A1 (es) Un compuesto de alfa-(n-sulfonamido) acetamida con un inhibidor de produccion de peptido beta amiloide
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
BR122018014454B8 (pt) forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
GT200900057A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
CL2007002197A1 (es) Compuestos derivados de indol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes mellitus, retinopatia diabetica, hiperglucemia, hiperl
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
CL2010001526A1 (es) Compuestos derivados de isonicotinamida, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que comprende un compuesto;utiles para tratar enfermedades relacionadas con dislipidemia y trastornos del metabolismo de lipidos.
MX384206B (es) Formulaciones de inhibidores de dpp iv
TNSN07425A1 (fr) Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol,l'eugenol, le thymol, le borneol, le carvacrol, et les ionones alpha-et-beta-.
CL2007002187A1 (es) Compuestos derivados espirocetal sustituidos; composicion farmaceutica que comprende a dicho compuesto; y su uso para el tratamiento de la diabetes, hiperglicemia, complicaciones diabeticas y obesidad.
HN2006000971A (es) Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1
SV2006002134A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis ref. 5195-sv
EA200702486A1 (ru) Противовирусная, противоопухолевая или противопаразитарная фармацевтическая композиция и ее применение
BRPI0513812B8 (pt) método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical
BRPI0618380A2 (pt) combinação farmacêutica e seu uso
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
BR112015023209A2 (pt) novos medicamentos compreendendo uma composição de anticorpo enrriquecida com uma carga principal de isoforma
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
DOP2010000088A (es) Compuesto inhibidor de fosforilasa de glicógeno y composición farmacéutica del mismo.
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B15K Others concerning applications: alteration of classification

Ipc: A61K 45/06 (2006.01), A61P 31/00 (2006.01), A61P 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2670 DE 08-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.